Physician profile
Brian W Ward
NPI 1366494643
$8,172.04
in general payments reported to CMS, 2019-2025
32 companies · $2,669 in 2025
The $2,669 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,095 · 2020: $245 · 2021: $568 · 2022: $672 · 2023: $1,147 · 2024: $1,775 · 2025: $2,669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,456 · Education: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,455.68 |
| Education | $136.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,105.67 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $998.50 | 2019-2025 | Tremfya, Stelara, Simponi |
| Gilead Sciences, INC. | $907.93 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $729.26 | 2019-2025 | Entyvio |
| Aimmune Therapeutics, INC. | $678.99 | 2024-2025 | Zenpep |
| Genzyme Corporation | $590.11 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $530.95 | 2019-2025 | Xifaxan, Trulance |
| Qol Medical, LLC | $461.00 | 2019-2024 | Sucraid |
| Madrigal Pharmaceuticals | $333.20 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $221.93 | 2022-2025 | Dupixent |
| Pfizer INC. | $209.41 | 2019-2025 | |
| Celgene Corporation | $196.03 | 2022-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $165.94 | 2019-2024 | Linzess |
| Ardelyx, INC. | $141.11 | 2023-2025 | Ibsrela |
| Lilly USA, LLC | $137.54 | 2023-2025 | Omvoh |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $119.66 | 2025 | Voquezna |
| Amgen INC. | $117.20 | 2025 | Uplizna |
| Intercept Pharmaceuticals, INC. | $90.39 | 2019-2025 | Ocaliva |
| Ferring Pharmaceuticals INC. | $87.00 | 2019-2025 | Rebyota |
| Merck Sharp & Dohme LLC | $75.68 | 2019-2024 | Dificid |
| Ipsen Biopharmaceuticals, INC | $45.85 | 2024-2025 | Iqirvo |
| Celltrion USA INC. | $35.69 | 2025 | Vegzelma |
| Organon LLC | $35.43 | 2024-2025 | Hadlima |
| Nestle Healthcare Nutrition INC. | $29.43 | 2021-2023 | |
| Covidien LP | $23.42 | 2019 | |
| Janssen Pharmaceuticals, INC | $20.96 | 2025 | |
| Welch Allyn | $16.90 | 2021 | |
| Novo Nordisk INC | $16.03 | 2025 | Wegovy |
| Daiichi Sankyo INC. | $14.99 | 2023 | Injectafer |
| Baxter Healthcare | $12.67 | 2022 | |
| Ucb, INC. | $12.00 | 2019 | |
| Allergan, INC. | $11.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.